Bradley Freilich, MD
Gastroenterology · Kansas City, MONPI 1659424810
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Intercept Pharmaceuticals, Inc. at 34.6% of the total. Reporting peaked in 2019 at $6,111 and has fallen 75.8% since, to $1,481 in 2025.
Across 350 payments — averaging $73.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$9K
- Novo Nordisk$3K
- Dova Pharmaceuticals$3K
- Endogastric Solutions, Inc$2K
- AbbVie$2K
- Gilead$1K
- plus $6K from 38 others
Across 997 payments — averaging $4474.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$1.4M
- Madrigal Pharmaceuticals$826K
- Eli Lilly$371K
- Gilead$329K
- Genentech, Inc.$307K
- Seqirus USA Inc$306K
- plus $956K from 15 others
What the payments were for
- Consulting fees$6,06424%
- Speaking & faculty fees$9,44537%
- Travel & lodging$2,59110%
- Food & beverage$7,59230%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,718 in reported general payments places this provider in the 85th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 36 | $56,497 |
| LinzessLinaclotide | 39 | $22,076 |
| OzempicSemaglutide | 12 | $13,847 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 43 | $6,835 |
| ErythromycinErythromycin Base | 18 | $5,786 |
| Ursodiol | 32 | $5,468 |
| Mesalamine | 17 | $4,990 |
| Famotidine | 194 | $4,140 |
| Mycophenolate Mofetil | 29 | $3,820 |
| Colestipol Hcl | 30 | $2,794 |
| Budesonide EcBudesonide | 12 | $1,560 |
| Omeprazole | 39 | $957 |
| Azathioprine | 14 | $555 |
| Spironolactone | 33 | $550 |
| Pantoprazole Sodium | 21 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $161 | $56,49736 claims |
| AbbVieLinzess | $1,507 | $22,07639 claims |
| Novo NordiskOzempic | $2,901 | $13,84712 claims |
| Braintree Laboratories, Inc.Sutab | $45 | $6,83543 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Kansas City
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Tahar MahmoudiKansas City$114K
- Hillary BownikKansas City$85K
- Amit RastogiKansas City$63K
- Rajiv ChhabraKansas City$29K
- Prashant PandyaKansas City$21K
- Syed JafriKansas City$20K
- Gregory MerrittKansas City$16K
- Gregory SayukSaint Louis$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.